✦ LIBER ✦

1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

✍ Scribed by T. Trarbach; J. Drevs; D. Strumberg; T.C. Gauler; V. Schneider; W.E. Eberhardt; B. Collins; M. Marotti; A.J. Swaisland

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I open-label study of cediranib, a

✍ Tanja Trarbach, Beate Schultheis, Thomas C. Gauler, Vesile Schneider, Dirk Strum 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 379 KB

Phase I, dose escalation and pharmacokin

✍ Noboru Yamamoto; Tomohide Tamura; Nobuyuki Yamamoto; Kazuhiko Yamada; Yasuhide Y 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 436 KB

1202 ORAL A Phase I Study of the Potent

✍ L.R. Molife; S. Minton; J. Vitfell-Pedersen; E. Chen; D. Sullivan; L. Yan; A.M. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 64 KB

1246 POSTER A Phase I Dose-escalation St

✍ G.S. Falchook; S. Fu; H.M. Amin; S.A. Piha-Paul; D.S. Hong; A. Naing; M.B. Kleve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

The insulin-like growth factor-I recepto

✍ Molife, L R; Fong, P C; Paccagnella, L; Reid, A H M; Shaw, H M; Vidal, L; Arkena 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 469 KB